Stockscreener 앱 받기
16.36
2.04%
-0.34
시간 외 거래:
16.36
Vtv Therapeutics Inc 주식(VTVT)의 최신 뉴스
(VTVT) Technical Data - news.stocktradersdaily.com
vTv resumes Phase III oral T1D drug study - The Pharma Letter
vTv Therapeutics appoints new CFO amid Phase 3 trial By Investing.com - Investing.com South Africa
vTv Therapeutics Appoints New CFO Amidst Phase 3 Trial - TipRanks
vTv Therapeutics Appoints Michael Tung, M.D., MBA, As Chief Financial Officer - citybiz
VTv Therapeutics Names Michael Tung as Finance Chief - marketscreener.com
vTv Therapeutics (VTVT) Appoints New CFO | VTVT Stock News - GuruFocus
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief Fina - GuruFocus
VTv Therapeutics Names Michael Tung CFO, Effective Immediately - Nasdaq
vTv Therapeutics appoints new CFO amid Phase 3 trial - Investing.com
vTv Therapeutics Appoints Michael Tung, M.D., MBA, to Chief - GlobeNewswire
vTv Therapeutics Advances First-in-Class Oral Type 1 Diabetes Drug as New CFO Joins - Stock Titan
VTv Therapeutics: Q1 Earnings Snapshot - Bluefield Daily Telegraph
How to Take Advantage of moves in (VTVT) - news.stocktradersdaily.com
vTv Therapeutics Highlights Cadisegliatin’s Potential for Diabetes - TipRanks
VTVT Advances Cadisegliatin Program with Phase 3 Study | VTVT St - GuruFocus
vTv Therapeutics advances type 1 diabetes trial By Investing.com - Investing.com South Africa
vTv Therapeutics Inc Reports Q1 2025 EPS of -$0.77, Beating Estimates; Net Loss at $5.1 Million - GuruFocus
vTv Therapeutics Announces 2025 First Quarter Financial Results and Provides Corporate Update - The Manila Times
vTv Therapeutics Accelerates Timeline for First-Ever Oral Type 1 Diabetes Drug as Phase 3 Trial Advances - Stock Titan
VTV Therapeutics Announces Reinitiation Of Screening In CATT1 Phase 3 Trial - marketscreener.com
vTv Therapeutics advances type 1 diabetes trial - Investing.com Australia
VTv Therapeutics Resumes Cadisegliatin Testing in Type 1 Diabetes - marketscreener.com
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treat - GuruFocus
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes | VTVT Stock New - GuruFocus
vTv Therapeutics (VTVT) Resumes Phase 3 Trial for Diabetes Treatment | VTVT Stock News - GuruFocus
vTv Therapeutics Announces Reinitiation of CATT1 Phase 3 Trial for Cadisegliatin, Shortens Duration to Expedite Topline Data Expected in 2026 - Nasdaq
vTv Therapeutics Announces Reinitiation of Screening in - GlobeNewswire
vTv Therapeutics Announces Reinitiation of Screening in CATT1 Phase 3 Trial Evaluating Potential First-in-Class Liver-Selective Glucokinase Activator Cadisegliatin for Type 1 Diabetes - Stock Titan
How the (VTVT) price action is used to our Advantage - news.stocktradersdaily.com
vTv Therapeutics Inc expected to post a loss of 81 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Has $158,000 Holdings in vTv Therapeutics Inc. (NASDAQ:VTVT) - Defense World
vTv Therapeutics (VTVT) to Release Quarterly Earnings on Thursday - Defense World
vTv Therapeutics Stock Price, Quotes and Forecasts | NASDAQ:VTVT - Benzinga
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at StockNews.com - Defense World
vTv Therapeutics Appoints Barry Brown as Interim CFO - MSN
vTv Therapeutics (NASDAQ:VTVT) Coverage Initiated at HC Wainwright - Defense World
Q1 Earnings Forecast for VTVT Issued By HC Wainwright - Defense World
HC Wainwright Initiates vTv Therapeutics With Buy Rating, $36 Price Target - MarketScreener
This Couchbase Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday - Benzinga
HC Wainwright & Co. Initiates Coverage of vTv Therapeutics (VTVT) with Buy Recommendation - Nasdaq
H.C. Wainwright sets $36 target for vTv Therapeutics stock By Investing.com - Investing.com Canada
H.C. Wainwright sets $36 target for vTv Therapeutics stock - Investing.com
(VTVT) Trading Advice - news.stocktradersdaily.com
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com - Defense World
(VTVT) Trading Signals - news.stocktradersdaily.com
0.95%
자본화:
|
볼륨(24시간):